Globalepolicy.org is a free to access global medical news service for the consumer, professional and researcher.


             
 

Background: A treatment algorithm and screening examination have been developed to guide patient management and prospectively determine potential for highly active individuals to succeed with nonoperative care after anterior cruciate ligament rupture.

Objective: To prospectively characterize and classify the entire population of highly active individuals over a 10-year period and provide final outcomes for individuals who elected nonoperative care.

Methods: Inclusion criteria included presentation within 7 months of the index injury and an International Knee Documentation Committee level I or II activity level before injury. Concomitant injury, unresolved impairments, and a screening examination were used as criteria to guide management and classify individuals as noncopers (poor potential) or potential copers (good potential) for nonoperative care.

Results: A total of 832 highly active patients with subacute anterior cruciate ligament tears were seen over the 10-year period; 315 had concomitant injuries, 87 had unresolved impairments, and 85 did not participate in the classification algorithm. The remaining 345 patients (216 men, 129 women) participated in the screening examination a mean of 6 weeks after the index injury. There were 199 subjects classified as noncopers and 146 as potential copers. Sixty-three of 88 potential copers successfully returned to preinjury activities without surgery, with 25 of these patients not undergoing anterior cruciate ligament reconstruction at the time of follow-up.

Conclusion: The classification algorithm is an effective tool for prospectively identifying individuals early after anterior cruciate ligament injury who want to pursue nonoperative care or must delay surgical intervention and have good potential to do so.



NAVIGATION


         

 

Roche Diagnostics announced that the U.S. Food and Drug Administration (FDA) has granted CLIA-waived status to the CoaguChek® XS Plus system, a point-of-care anticoagulation monitor that offers connectivity and data management tools to help healthcare professionals manage PT/INR (blood clotting time) testing…

 

Preliminary research on cancer treatments using nanotechnology and laser therapy has led to a National Science Foundation (NSF) Faculty Early Career Development (CAREER) award for Marissa Nichole Rylander, Virginia Tech assistant professor jointly appointed in the Department of Mechanical Engineering and Virginia Tech - Wake Forest University School of Biomedical Engineering and Sciences (SBES)…

 

People with severe stomach disorders can sometimes suffer from chronic vomiting. This symptom can be treated with electrical impulses from a pacemaker in the stomach…

 

Early detection through physical examination is one of the key factors in successfully treating prostate cancer. Now, health care providers will be able to gain applied training early in their medical education and careers with new simulation technology developed at the University of Virginia that will allow them to experience numerous scenarios that simulate prostate cancer…

 

Background The ability of short-acting insulin secretagogues to reduce the risk of diabetes or cardiovascular events in people with impaired glucose tolerance is unknown.

Methods In a double-blind, randomized clinical …

 

Background It is not known whether drugs that block the renin-angiotensin system reduce the risk of diabetes and cardiovascular events in patients with impaired glucose tolerance.

Methods In this double-blind, …

 

AngioScore, Inc., a developer of novel angioplasty catheters for use in the treatment of cardiovascular disease, announced that the company has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its AngioSculpt® PTA Scoring Balloon Catheter for dilatation of lesions in renal arteries…

 

Torax Medical Inc., a medical device company focused on the minimally invasive treatment of gastro-esophageal reflux disease (GERD), has received CE Mark for its LINX® Anti-Reflux treatment.. The company has started commercial launch of the LINX device at select centers in Europe…

 

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of ophthalmic sustained release drug delivery products, today said that a recently-published peer reviewed scientific paper showed that a sustained release Durasert drug delivery device releasing the steroid fluocinolone acetonide (FA) in the back of the eye preserved retinal function in a retinitis pigmentosa model. Dr…

 

GE Healthcare (NYSE: GE) announced that an important new feature has been added to its LOGIQ E9 platform; elastography. The enhanced device is on display at the American Institute of Ultrasound in Medicine’s (AIUM) 2010 Annual Convention in San Diego (booth 301)…




March 2010
Mon Tue Wed Thu Fri Sat Sun
« Feb   Apr »
1234567
891011121314
15161718192021
22232425262728
293031